Twelfth Amendment to Services Agreement between Cara Therapeutics, Inc. and Bio Diligence Partners, Inc.

Contract Categories: Business Operations › Services Agreements
Summary

Cara Therapeutics, Inc. and Bio Diligence Partners, Inc. have agreed to extend their existing Services Agreement until July 1, 2017. Under this amendment, Bio Diligence Partners will continue to receive an annual compensation of $157,500, paid monthly, and full reimbursement of health insurance costs, paid quarterly. All other terms of the original agreement remain unchanged.

Read More Arrow
EX-10.1 2 d204489dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

 

October 1, 2016

Michael Lewis, Ph.D.

Bio Diligence Partners, Inc.,

This letter shall serve as a twelfth amendment to the Services Agreement dated July 2, 2004. It is hereby agreed to extend the Agreement from October 1, 2016 to July 1, 2017. Compensation described in Exhibit A of the Agreement, as previously amended, will continue at the rate of $157,500.00 per annum and paid on a monthly basis. The reimbursement for 100% of the health insurance cost shall continue, paid quarterly.

All other sections of the Agreement continue as written.

 

Cara Therapeutics, Inc.
By:  

/s/ Derek Chalmers

Name:   Derek Chalmers, Ph.D., D.Sc.
Title:   President & CEO
Bio Diligence Partners, Inc.
By:  

/s/ Michael Lewis

Name:   Michael Lewis, Ph.D.
Title:   President